



Amendments to the Claims

Claim 1 (original) A compound of Formula I:



where:

R¹ is (C₃-C₇ cycloalkyl)₀₋₁(C₁-C₆ alkyl), (C₃-C₇ cycloalkyl)₀₋₁(C₂-C₆ alkenyl), (C₃-C₇ cycloalkyl)₀₋₁(C₂-C₆ alkynyl) or C₃-C₇ cycloalkyl, each optionally substituted with up to three groups independently selected from halo, hydroxy, thiol, cyano, trifluoromethyl, trifluoromethoxy, C₁-C₇ alkoxy, C₃-C₇ cycloalkoxy, oxo, and NR⁴R⁵, biphenyl optionally




substituted with halo, hydrogen,


R² is C₁-C₃ alkyl, benzyl optionally monosubstituted in the phenyl ring with a substituent selected from the group consisting of halo, C₁-C₆ alkoxy optionally substituted in the alkyl chain with C₃-C₇ cycloalkyl, and C₁-C₆ alkylthio optionally substituted in the alkyl chain with C₃-C₇ cycloalkyl, or benzyl optionally disubstituted in the phenyl ring with a first substituent independently selected from halo and a second substituent independently selected from halo, C₁-C₆ alkoxy optionally substituted in the alkyl chain with C₃-C₇ cycloalkyl, and C₁-C₆ alkylthio optionally substituted in the alkyl chain with C₃-C₇ cycloalkyl;

R³ is:


i) a piperidin-2-yl moiety of formula:



ii) a tetrahydropyridin-2-yl moiety of formula:



iii) a piperazin-2-yl moiety of formula:



- iv) homopiperidin-2-yl;
- v) 1,2,3,4-tetrahydroisoquinolin-3-yl optionally substituted with one or two substituents selected from halo, C₁-C₆ alkyl, and C₁-C₆ alkoxy;
- vi) 2-azabicyclo[2.2.2]oct-(5Z)ene-3-yl;
- vii) 2-azabicyclo[2.2.1]hept-3-yl optionally substituted with C₁-C₁₀ alkyl optionally substituted with C₁-C₄ alkoxy; or
- viii) 2-azabicyclo[2.2.2]oct-3-yl optionally substituted with oxo, or optionally substituted with one or two substituents independently selected from hydroxy, fluoro, and C₁-C₆ alkyl;

X is CH, N, or N⁺-O⁻;

Y is CR¹¹, N, or N⁺-O⁻;

Q is CR¹², N, or N⁺-O⁻;

R⁴ is hydrogen, C₁-C₆ alkyl optionally substituted up to three times with fluoro, or phenyl;

R⁵ is hydrogen, C₁-C₆ alkyl optionally substituted up to three times with fluoro, phenyl, -C(O)(C₁-C₆ alkyl optionally substituted up to three times with fluoro), or -SO₂(C₁-C₆ alkyl optionally substituted up to three times with fluoro);

R⁶ and R⁷ are independently selected from the group consisting of methyl, ethyl, and propyl;

R⁸ is hydrogen or C₁-C₆ alkyl;

R⁹ is C₃-C₅ cycloalkyl, sec-butyl, or -CH₂R¹³;

R¹⁰ is -CF₂R¹⁴, -OR¹⁵, -CH₂C(O)CH₃, -S(O)₁₋₂R¹⁶, -NR¹⁷SO₂R¹⁸, (C₁-C₃ alkoxy)-carbonyl, phenyl optionally substituted with halo, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,1-

dioxo-2,3,4,5-tetrahydroisothiazol-2-yl, or tetrazol-5-yl optionally substituted with C₁-C₃ alkyl;

R¹¹ is hydrogen, chloro, isobutyl, CH₂R¹⁹; CF₂R²⁰, 1,1,1-trifluoro-2-hydroxyeth-2-yl, C₂-C₄ alkenyl optionally substituted with one or two fluorine atoms, OR²¹, C(O)R²², N(methyl)(methylsulfonyl), N(methyl)(acetyl), pyrrolidin-2-on-1-yl, methylsulfonyl, N,N-dimethylaminosulfonyl, phenyl optionally substituted with one or two substituents selected from the group consisting of hydroxymethyl, methoxy, fluoro, and methylsulfonyl, 1,3-dioxolan-2-yl, 1,3-dithiolan-2-yl, 1,3-oxathiolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithian-2-yl, pyridinyl, thiazolyl, oxazolyl, or 1,2,4-oxadiazolyl optionally substituted with methyl;

R¹² is hydrogen or fluoro;

R¹³ is ethynyl or cyclopropyl;

R¹⁴ is hydrogen or methyl;

R¹⁵ is difluoromethyl or methanesulfonyl;

R¹⁶ is C₁-C₄ alkyl, C₃-C₆ cycloalkyl, phenyl, or -NR²⁵R²⁶;

R¹⁷ is hydrogen, C₁-C₃ alkyl optionally substituted with up to 3 fluorine atoms, or C₃-C₆ cycloalkyl;

R¹⁸ is C₁-C₃ alkyl or C₃-C₆ cycloalkyl;

R¹⁹ is fluoro, hydroxy, or C₁-C₃ alkoxy;

R²⁰ is hydrogen, phenyl, or furyl;

R²¹ is C₁-C₃ alkyl optionally substituted with one or two fluorine atoms;

R²² is C₁-C₃ alkyl, C₃-C₅ cycloalkyl, C₂-C₃ alkenyl, C₁-C₃ alkoxy, NR²³R²⁴, pyrrolidin-1-yl optionally substituted with methyl or one or two fluorine atoms, piperidin-1-yl, phenyl, pyridinyl, or furyl;

R²³ is hydrogen or methyl;

R²⁴ is methyl, ethyl, or propyl;

R²⁵ is hydrogen or methyl;

R²⁶ is methyl; or

R²⁵ and R²⁶ taken together with the nitrogen atom to which they are attached form a pyrrolidine or piperidine ring;

R²⁹ is hydrogen or C₁-C₆ alkyl;

R³⁰ is hydrogen or C₁-C₆ alkyl;

R²⁹ and R³⁰ taken together with the carbon to which they are attached form a C₃-C₆ cycloalkyl ring;

R^{31} is hydrogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or phenyl optionally monosubstituted with C_1 - C_6 alkyl;

R^{32} is hydrogen, R^{33} , or $-(CH_2)_{0-2}-OR^{33}$;

R^{33} is C_1 - C_{10} alkyl optionally substituted with 1-6 fluorine atoms, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, or $-(CH_2)_{0-3}-R^{34}$;

R^{34} is C_3 - C_7 cycloalkyl or phenyl each optionally substituted with one or two substituents independently selected from the group consisting of halo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, trifluoromethyl, and trifluoromethoxy, thienyl optionally substituted with halo, benzothienyl optionally substituted with halo, thiazolyl optionally substituted with C_1 - C_4 alkyl, or adamantyl;


R^{35} is $-(CH_2)_{0-6}-R^{34}$, $-C(O)-(CH_2)_{0-6}-R^{34}$, $-C(O)-(C_1-C_{10} \text{ alkyl})$, $-C(O)-(C_1-C_4 \text{ alkoxy optionally substituted with phenyl})$, C_1 - C_{10} alkyl optionally substituted with 1-6 fluorine atoms, C_2 - C_{10} alkenyl, or C_2 - C_{10} alkynyl;

R^{36} and R^{37} are both hydrogen or, taken together with the carbon atom to which they are attached form a carbonyl group; or a pharmaceutically acceptable salt thereof; provided that: a) no more than one of X, Y, and Q may be N or N^+-O^- ; and b) when X is CH, Y is CR^{11} , and Q is CR^{12} , then one of R^{11} and R^{12} is other than hydrogen.

Claims 2-5 (canceled)

Claim 6 (original): A pharmaceutical formulation comprising a compound of Claim 1, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

Claim 7 (original): A compound of Formula III:




III

where:

R^1 is $(C_3-C_7 \text{ cycloalkyl})_{0-1}(C_1-C_6 \text{ alkyl})$, $(C_3-C_7 \text{ cycloalkyl})_{0-1}(C_2-C_6 \text{ alkenyl})$, $(C_3-C_7 \text{ cycloalkyl})_{0-1}(C_2-C_6 \text{ alkynyl})$ or $C_3-C_7 \text{ cycloalkyl}$, each optionally substituted with up to three groups independently selected from halo, hydroxy, thiol, cyano, trifluoromethyl,

trifluoromethoxy, C₁-C₇ alkoxy, C₃-C₇ cycloalkoxy, oxo, and NR⁴R⁵, biphenyl optionally




substituted with halo, hydrogen,


R² is C₁-C₃ alkyl, benzyl optionally monosubstituted in the phenyl ring with a substituent selected from the group consisting of halo, C₁-C₆ alkoxy optionally substituted in the alkyl chain with C₃-C₇ cycloalkyl, and C₁-C₆ alkylthio optionally substituted in the alkyl chain with C₃-C₇ cycloalkyl, or benzyl optionally disubstituted in the phenyl ring with a first substituent independently selected from halo and a second substituent independently selected from halo, C₁-C₆ alkoxy optionally substituted in the alkyl chain with C₃-C₇ cycloalkyl, and C₁-C₆ alkylthio optionally substituted in the alkyl chain with C₃-C₇ cycloalkyl;

R^{3'} is:


ix) a piperidin-2-yl moiety of formula:



x) a tetrahydropyridin-2-yl moiety of formula:



xi) a piperazin-2-yl moiety of formula:



xii) homopiperidin-2-yl substituted in the 1-position with variable R²⁸,

- xiii) 1,2,3,4-tetrahydroisoquinolin-3-yl substituted in the 1-position with variable R^{28} and optionally further substituted with one or two substituents selected from halo, C_1 - C_6 alkyl, and C_1 - C_6 alkoxy;
- xiv) 2-azabicyclo[2.2.2]oct-(5Z)ene-3-yl substituted in the 2-position with variable R^{28} ;
- xv) 2-azabicyclo[2.2.1]hept-3-yl substituted in the 2-position with variable R^{28} and optionally further substituted with C_1 - C_{10} alkyl optionally substituted with C_1 - C_4 alkoxy; or
- xvi) 2-azabicyclo[2.2.2]oct-3-yl substituted in the 2-position with variable R^{28} and optionally further substituted with oxo, or optionally further substituted with one or two substituents independently selected from hydroxy, fluoro, and C_1 - C_6 alkyl;

X is CH, N, or N^+-O^- ;

Y is CR^{11} , N, or N^+-O^- ;

Q is CR^{12} , N, or N^+-O^- ;

R^4 is hydrogen, C_1 - C_6 alkyl optionally substituted up to three times with fluoro, or phenyl;

R^5 is hydrogen, C_1 - C_6 alkyl optionally substituted up to three times with fluoro, phenyl, $-C(O)(C_1$ - C_6 alkyl optionally substituted up to three times with fluoro), or $-SO_2(C_1$ - C_6 alkyl optionally substituted up to three times with fluoro);

R^6 and R^7 are independently selected from the group consisting of methyl, ethyl, and propyl;

R^8 is hydrogen or C_1 - C_6 alkyl;

R^9 is C_3 - C_5 cycloalkyl, sec-butyl, or $-CH_2R^{13}$;

R^{10} is $-CF_2R^{14}$, $-OR^{15}$, $-CH_2C(O)CH_3$, $-S(O)_{1-2}R^{16}$, $-NR^{17}SO_2R^{18}$, (C_1 - C_3 alkoxy)-carbonyl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,1-dioxo-2,3,4,5-tetrahydroisothiazol-2-yl, or tetrazol-5-yl optionally substituted with C_1 - C_3 alkyl;

R^{11} is hydrogen, chloro, isobutyl, CH_2R^{19} , CF_2R^{20} , 1,1,1-trifluoro-2-hydroxyeth-2-yl, C_2 - C_4 alkenyl optionally substituted with one or two fluorine atoms, OR^{21} , $C(O)R^{22}$, N(methyl)(methylsulfonyl), N(methyl)(acetyl), pyrrolidin-2-on-1-yl, methylsulfonyl, N,N-dimethylaminosulfonyl, phenyl optionally substituted with one or two substituents selected from the group consisting of hydroxymethyl, methoxy, fluoro, and methylsulfonyl, 1,3-

dioxolan-2-yl, 1,3-dithiolan-2-yl, 1,3-oxathiolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithian-2-yl, pyridinyl, thiazolyl, oxazolyl, or 1,2,4-oxadiazolyl optionally substituted with methyl;

R¹² is hydrogen or fluoro;

R¹³ is ethynyl or cyclopropyl;

R¹⁴ is hydrogen or methyl;

R¹⁵ is difluoromethyl or methanesulfonyl;

R¹⁶ is C₁-C₄ alkyl, C₃-C₆ cycloalkyl, phenyl, or -NR²⁵R²⁶;

R¹⁷ is hydrogen, C₁-C₃ alkyl optionally substituted with up to 3 fluorine atoms, or C₃-C₆ cycloalkyl;

R¹⁸ is C₁-C₃ alkyl or C₃-C₆ cycloalkyl;

R¹⁹ is fluoro, hydroxy, or C₁-C₃ alkoxy;

R²⁰ is hydrogen, phenyl, or furyl;

R²¹ is C₁-C₃ alkyl optionally substituted with one or two fluorine atoms;

R²² is C₁-C₃ alkyl, C₃-C₅ cycloalkyl, C₂-C₃ alkenyl, C₁-C₃ alkoxy, NR²³R²⁴, pyrrolidin-1-yl optionally substituted with methyl or one or two fluorine atoms, piperidin-1-yl, phenyl, pyridinyl, or furyl;

R²³ is hydrogen or methyl;

R²⁴ is methyl, ethyl, or propyl;

R²⁵ is hydrogen or methyl;

R²⁶ is methyl; or

R²⁵ and R²⁶ taken together with the nitrogen atom to which they are attached form a pyrrolidine or piperidine ring;

R²⁷ is hydrogen or a nitrogen protecting group;

R²⁸ is hydrogen or a nitrogen protecting group;

R²⁹ is hydrogen or C₁-C₆ alkyl;

R³⁰ is hydrogen or C₁-C₆ alkyl;

R²⁹ and R³⁰ taken together with the nitrogen to which they are attached form a C₃-C₆ cycloalkyl ring;

R³¹ is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, or phenyl optionally monosubstituted with C₁-C₆ alkyl;

R³² is hydrogen, R³³, or -(CH₂)₀₋₂-OR³³;

R³³ is C₁-C₁₀ alkyl optionally substituted with 1-6 fluorine atoms, C₂-C₆ alkenyl, C₂-C₆ alkynyl, or -(CH₂)₀₋₃-R³⁴;


R^{34} is C₃-C₇ cycloalkyl or phenyl each optionally substituted with one or two substituents independently selected from the group consisting of halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy, trifluoromethyl, and trifluoromethoxy, thienyl optionally substituted with halo, benzothienyl optionally substituted with halo, thiazolyl optionally substituted with C₁-C₄ alkyl, or adamantyl;

R^{35} is $-(CH_2)_{0-6}-R^{34}$, $-C(O)-(CH_2)_{0-6}-R^{34}$, $-C(O)-(C_1-C_{10} \text{ alkyl})$, $-C(O)-(C_1-C_4 \text{ alkoxy optionally substituted with phenyl})$, C₁-C₁₀ alkyl optionally substituted with 1-6 fluorine atoms, C₂-C₁₀ alkenyl, or C₂-C₁₀ alkynyl;

R^{36} and R^{37} are both hydrogen or, taken together with the carbon atom to which they are attached form a carbonyl group;


R^{38} is hydrogen or an oxygen protecting group; or an acid addition salt thereof provided that: a) no more than one of X, Y, and Q may be N or N⁺-O⁻; b) when X is CH, Y is CR¹¹, and Q is CR¹², then one of R¹¹ and R¹² is other than hydrogen; and c) at least one of R²⁷, R²⁸, and R³⁸ is other than hydrogen.

Claim 8 (original): A compound of Formula IV:



where:

R^1 is (C₃-C₇ cycloalkyl)₀₋₁(C₁-C₆ alkyl), (C₃-C₇ cycloalkyl)₀₋₁(C₂-C₆ alkenyl), (C₃-C₇ cycloalkyl)₀₋₁(C₂-C₆ alkynyl) or C₃-C₇ cycloalkyl, each optionally substituted with up to three groups independently selected from halo, hydroxy, thiol, cyano, trifluoromethyl, trifluoromethoxy, C₁-C₇ alkoxy, C₃-C₇ cycloalkoxy, oxo, and NR⁴R⁵, biphenyl optionally




substituted with halo, hydrogen,


R^2 is C_1 - C_3 alkyl, benzyl optionally monosubstituted in the phenyl ring with a substituent selected from the group consisting of halo, C_1 - C_6 alkoxy optionally substituted in the alkyl chain with C_3 - C_7 cycloalkyl, and C_1 - C_6 alkylthio optionally substituted in the alkyl chain with C_3 - C_7 cycloalkyl, or benzyl optionally disubstituted in the phenyl ring with a first substituent independently selected from halo and a second substituent independently selected from halo, C_1 - C_6 alkoxy optionally substituted in the alkyl chain with C_3 - C_7 cycloalkyl, and C_1 - C_6 alkylthio optionally substituted in the alkyl chain with C_3 - C_7 cycloalkyl;

$R^{3'}$ is:


- ix) a piperidin-2-yl moiety of formula:



- x) a tetrahydropyridin-2-yl moiety of formula:



- xii) a piperazin-2-yl moiety of formula:



- xii) homopiperidin-2-yl substituted in the 1-position with variable R^{28} ;
 xiii) 1,2,3,4-tetrahydroisoquinolin-3-yl substituted in the 1-position with variable R^{28} and optionally further substituted with one or two substituents selected from halo, C_1 - C_6 alkyl, and C_1 - C_6 alkoxy;
 xiv) 2-azabicyclo[2.2.2]oct-(5Z)ene-3-yl substituted in the 2-position with variable R^{28} ;

- xv) 2-azabicyclo[2.2.1]hept-3-yl substituted in the 2-position with variable R^{28} and optionally further substituted with C_1 - C_{10} alkyl optionally substituted with C_1 - C_4 alkoxy; or
- xvi) 2-azabicyclo[2.2.2]oct-3-yl substituted in the 2-position with variable R^{28} and optionally further substituted with oxo, or optionally further substituted with one or two substituents independently selected from hydroxy, fluoro, and C_1 - C_6 alkyl;

X is CH, N, or N^+-O^- ;

Y is CR^{11} , N, or N^+-O^- ;

Q is CR^{12} , N, or N^+-O^- ;

R^4 is hydrogen, C_1 - C_6 alkyl optionally substituted up to three times with fluoro, or phenyl;

R^5 is hydrogen, C_1 - C_6 alkyl optionally substituted up to three times with fluoro, phenyl, $-C(O)(C_1$ - C_6 alkyl optionally substituted up to three times with fluoro), or $-SO_2(C_1$ - C_6 alkyl optionally substituted up to three times with fluoro);

R^6 and R^7 are independently selected from the group consisting of methyl, ethyl, and propyl;

R^8 is hydrogen or C_1 - C_6 alkyl;

R^9 is C_3 - C_5 cycloalkyl, sec-butyl, or $-CH_2R^{13}$;

R^{10} is $-CF_2R^{14}$, $-OR^{15}$, $-CH_2C(O)CH_3$, $-S(O)_{1-2}R^{16}$, $-NR^{17}SO_2R^{18}$, (C_1 - C_3 alkoxy)-carbonyl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,1-dioxo-2,3,4,5-tetrahydroisothiazol-2-yl, or tetrazol-5-yl optionally substituted with C_1 - C_3 alkyl;

R^{11} is hydrogen, chloro, isobutyl, CH_2R^{19} , CF_2R^{20} , 1,1,1-trifluoro-2-hydroxyethyl-2-yl, C_2 - C_4 alkenyl optionally substituted with one or two fluorine atoms, OR^{21} , $C(O)R^{22}$, N(methyl)(methylsulfonyl), N(methyl)(acetyl), pyrrolidin-2-on-1-yl, methylsulfonyl, N,N-dimethylaminosulfonyl, phenyl optionally substituted with one or two substituents selected from the group consisting of hydroxymethyl, methoxy, fluoro, and methylsulfonyl, 1,3-dioxolan-2-yl, 1,3-dithiolan-2-yl, 1,3-oxathiolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithian-2-yl, pyridinyl, thiazolyl, oxazolyl, or 1,2,4-oxadiazolyl optionally substituted with methyl;

R^{12} is hydrogen or fluoro;

R^{13} is ethynyl or cyclopropyl;

R^{14} is hydrogen or methyl;

R^{15} is difluoromethyl or methanesulfonyl;

R¹⁶ is C₁-C₄ alkyl, C₃-C₆ cycloalkyl, phenyl, or -NR²⁵R²⁶;

R¹⁷ is hydrogen, C₁-C₃ alkyl optionally substituted with up to 3 fluorine atoms, or C₃-C₆ cycloalkyl;

R¹⁸ is C₁-C₃ alkyl or C₃-C₆ cycloalkyl;

R¹⁹ is fluoro, hydroxy, or C₁-C₃ alkoxy;

R²⁰ is hydrogen, phenyl, or furyl;

R²¹ is C₁-C₃ alkyl optionally substituted with one or two fluorine atoms;

R²² is C₁-C₃ alkyl, C₃-C₅ cycloalkyl, C₂-C₃ alkenyl, C₁-C₃ alkoxy, NR²³R²⁴, pyrrolidin-1-yl optionally substituted with methyl or one or two fluorine atoms, piperidin-1-yl, phenyl, pyridinyl, or furyl;

R²³ is hydrogen or methyl;

R²⁴ is methyl, ethyl, or propyl;

R²⁵ is hydrogen or methyl;

R²⁶ is methyl; or

R²⁵ and R²⁶ taken together with the nitrogen atom to which they are attached form a pyrrolidine or piperidine ring;

R²⁸ is hydrogen or a nitrogen protecting group;

R²⁹ is hydrogen or C₁-C₆ alkyl;

R³⁰ is hydrogen or C₁-C₆ alkyl;

R²⁹ and R³⁰ taken together with the nitrogen to which they are attached form a C₃-C₆ cycloalkyl ring;

R³¹ is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, or phenyl optionally monosubstituted with C₁-C₆ alkyl;

R³² is hydrogen, R³³, or -(CH₂)₀₋₂-OR³³;

R³³ is C₁-C₁₀ alkyl optionally substituted with 1-6 fluorine atoms, C₂-C₆ alkenyl, C₂-C₆ alkynyl, or -(CH₂)₀₋₃-R³⁴;

R³⁴ is C₃-C₇ cycloalkyl or phenyl each optionally substituted with one or two substituents independently selected from the group consisting of halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy, trifluoromethyl, and trifluoromethoxy, thienyl optionally substituted with halo, benzothienyl optionally substituted with halo, thiazolyl optionally substituted with C₁-C₄ alkyl, or adamantyl;

R^{35} is $-(CH_2)_{0-6}-R^{34}$, $-C(O)-(CH_2)_{0-6}-R^{34}$, $-C(O)-(C_1-C_{10} \text{ alkyl})$, $-C(O)-(C_1-C_4 \text{ alkoxy})$ optionally substituted with phenyl, C_1-C_{10} alkyl optionally substituted with 1-6 fluorine atoms, C_2-C_{10} alkenyl, or C_2-C_{10} alkynyl;

R^{36} and R^{37} are both hydrogen or, taken together with the carbon atom to which they are attached form a carbonyl group;

R^{38} is hydrogen or an oxygen protecting group;

R^{39} and R^{40} are independently selected from methyl, ethyl, or propyl; or an acid addition salt thereof provided that no more than one of X, Y, and Q may be N or N^+-O^- .

Claim 9 (new): A method for the inhibition of production of A- β peptide comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 1.

Claim 10 (new): A method of inhibiting BACE in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 1.